kabutan

KISSEI PHARMA hits limit-down amid cautious administration guidance for Tabneoss

Mon May 18, 2026 1:58 pm JST Catalyst

Kissei Pharmaceutical Co., Ltd. <4547> shares hit their daily limit-down floor with unexecuted sell orders after the company issued a safety warning regarding its drug Tabneoss following the market close on May 15. The drug, an avacopan-based treatment for microscopic polyangiitis and granulomatosis with polyangiitis, will now be subject to cautious administration guidelines for healthcare professionals, sparking intense selling on concerns over an uncertain earnings outlook.

The company is urging healthcare professionals to refrain from prescribing the drug to new patients. For patients currently undergoing treatment, physicians are advised to carefully weigh whether to continue administration after informing them of hepatic impairment risks and alternative therapies. Kissei stated it is gathering safety data from Europe and the United States, providing necessary updates to the Pharmaceuticals and Medical Devices Agency (PMDA), and consulting with the Ministry of Health, Labour and Welfare. The potential impact on financial performance is currently under review.

Source: MINKABU PRESS

*Translated by generative AI. Click here for the original article.

Related Articles